VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma.

about

VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma.

Item

http://www.wikidata.org/entity/Q39103567

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

VTD-melphalan is well tolerate ...... ve status in multiple myeloma.

@en

VTD-melphalan is well tolerate ...... ve status in multiple myeloma.

@nl

type

Item

label

VTD-melphalan is well tolerate ...... ve status in multiple myeloma.

@en

VTD-melphalan is well tolerate ...... ve status in multiple myeloma.

@nl

prefLabel

VTD-melphalan is well tolerate ...... ve status in multiple myeloma.

@en

VTD-melphalan is well tolerate ...... ve status in multiple myeloma.

@nl

P1476

VTD-melphalan is well tolerate ...... ve status in multiple myeloma.

@en

P2093

Allyson Schultz

http://www.w3.org/2001/XMLSchema#string

Annick Tricot

http://www.w3.org/2001/XMLSchema#string

Guido Tricot

http://www.w3.org/2001/XMLSchema#string

Kalyan Nadiminti

http://www.w3.org/2001/XMLSchema#string

Kamal Kant Singh Abbi

http://www.w3.org/2001/XMLSchema#string

Sarah L Mott

http://www.w3.org/2001/XMLSchema#string

Sonya Behrends

http://www.w3.org/2001/XMLSchema#string

P2860

Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies

Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answers

New criteria for response assessment: role of minimal residual disease in multiple myeloma

Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation.

Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergrou

Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study.

Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du

High-dose melphalan with autologous bone marrow transplantation for multiple myeloma.

Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study

P304

217-226

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/OTT.S112423

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Fenghuang Zhan

Lindsay Dozeman

P577

2017-01-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28123303

http://www.w3.org/2001/XMLSchema#string

P932

5229169

http://www.w3.org/2001/XMLSchema#string